## Contents

- 7. Holding Company & Structure Optimization
- Popular Holding Jurisdictions
- Substance Requirements (Post-ATAD & EU Anti-Abuse)
- Patent Box / IP Box Regimes

## 7. Holding Company & Structure Optimization

### Popular Holding Jurisdictions

| Jurisdiction | Key Advantage | Structure | Effective Rate on Dividends Received |
|-------------|---------------|-----------|--------------------------------------|
| **Netherlands** | Participation exemption (deelnemingsvrijstelling) | BV holding | 0% on qualifying dividends and capital gains (≥5% shareholding) |
| **Luxembourg** | SOPARFI (Société de Participations Financières) | SA/SARL holding | 0% under participation exemption (≥10% or acquisition cost ≥€1.2M, held ≥12 months) |
| **Ireland** | IP regime + 12.5% trading rate | Irish HoldCo / IP Co | 12.5% on trading profits; participation exemption on disposals of substantial shareholdings |
| **Belgium** | DRD (Dividends Received Deduction) | SA/BV holding | 95% deduction on qualifying dividends (effective ~1.25% taxation) |
| **Cyprus** | IP box + exempt dividends | Ltd holding | 0% on dividends received; 0% on gains from disposal of securities |
| **Malta** | Full imputation + refund | Ltd holding | Effective 0-5% after shareholder refund |

### Substance Requirements (Post-ATAD & EU Anti-Abuse)

Since ATAD and the EU Code of Conduct Group crackdown, substance is critical:

- **Board of directors**: Majority should reside in the holding jurisdiction
- **Decision-making**: Key management decisions demonstrably made locally
- **Employees**: Qualified staff (not just a registered agent)
- **Office space**: Real premises (not a virtual office)
- **Bank accounts**: Active local bank accounts with genuine transactions
- **Operational expenditure**: Meaningful local costs proportionate to activities
- **Risk**: Without substance, benefits can be denied under GAAR, or entity reclassified as a conduit

### Patent Box / IP Box Regimes

*Last verified: Jun 2026. All EU IP boxes are **nexus-compliant** (OECD BEPS Action 5) — the benefit is proportional to self-performed R&D. Effective rates move when the underlying CIT changes (e.g. Luxembourg's CIT cut to 16% slightly lowers its IP-box effective rate, and Cyprus's 2026 jump to 15% CIT changes the base) — re-verify before quoting.*

| Country | Regime Name | Effective Rate (approx.) | Key Conditions |
|---------|------------|----------------|----------------|
| Belgium | Innovation Income Deduction | ~3.75% (85% deduction of qualifying income) | Nexus; R&D self-performed or group-outsourced |
| Cyprus | IP Box | ~2.5% (80% exemption); re-verify vs. new 15% CIT base | Nexus. Patents, copyrighted software |
| France | IP regime (Art. 238 CGI) | 10% (net) | Nexus. Patents, patentable inventions, copyrighted software |
| Hungary | IP regime | ~0–4.5% (50% exemption on royalties) | Broad IP definition |
| Ireland | Knowledge Development Box (KDB) | ~10% (relief reduces the 12.5% rate) | Nexus. Patents, copyrighted software; SME-friendly. Verify current relief at [Revenue](https://www.revenue.ie/). |
| Italy | "Patent Box" | 110% super-deduction on qualifying R&D costs | Reformed 2021: cost super-deduction, not income-based |
| Luxembourg | IP regime | ~5% (80% exemption; lower since CIT cut to 16%) | Nexus. Patents, copyrighted software, utility models |
| Netherlands | Innovation Box | 9% | Nexus. Self-developed patents, WBSO-qualifying R&D, software |
| Poland | IP Box | 5% | Nexus. Patents, copyrighted software, registered IP |
| Portugal | Patent Box | up to 85% exemption (effective single-digit) | Patents and industrial designs; verify current exemption % |
| Spain | Patent Box | ~10% (up to 60% reduction) | Nexus since 2016 reform |

**Nexus Approach** (OECD BEPS Action 5): IP-box benefits are limited proportionally to the R&D expenditure incurred by the taxpayer itself (vs. acquired IP). Formula: (qualifying expenditure / total expenditure) × 130% uplift (capped at 100%) × qualifying income. Robust **DEMPE** and substance analysis is expected — see §7 substance requirements.

---